| Report Code: 40153 | Published: January 2019 | Pages: 74 | Available format: |
| Therapeutic Area(s): | Others | Report Type: Indication Pipeline Reports |
Chapter 1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.3.1 Pipeline Analysis by Phase
1.3.2 Pipeline Analysis by Molecule Type
1.3.3 Pipeline Analysis by Route of Administration
1.4 Key Stakeholders
Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown of Primary Research Respondents
2.2.1.1 By industry participant
2.2.1.2 By company type
Chapter 3. Executive Summary
Chapter 4. Pipeline Outlook
4.1 Overview
4.2 Signs and Symptoms
4.3 Causes
4.4 Diagnosis
4.5 Treatment
4.6 Epidemiology
4.7 Key Drivers
4.7.1 Technological Advancements in Drug Development
4.7.2 Positive Clinical Results
4.8 Key Barriers
4.8.1 Increasing Healthcare Cost
4.9 Achondroplasia Therapeutics Pipeline Analysis
4.9.1 Pipeline Analysis by Phase
4.9.2 Pipeline Analysis by Molecule Type
4.9.3 Pipeline Analysis by Route of Administration
4.9.4 Pipeline Analysis by Company
Chapter 5. Achondroplasia Therapeutics Pipeline Analysis by Phase (2018) 24
5.1 Phase III
5.1.1 Vosoritide
5.1.1.1 Clinical trials
5.1.1.2 Clinical trial results
5.1.1.3 Strategic development
5.2 Phase I
5.2.1 TransCon CNP
5.2.1.1 Pre-Clinical studies
5.2.1.2 Clinical trials
5.2.1.3 Strategic development
5.2.1.4 Technology
5.2.2 XXXX
5.2.2.1 Pre-Clinical studies
5.2.2.2 Strategic development
5.2.2.3 Designation
5.3 Pre-Clinical
5.3.1 RBM 007
5.3.1.1 Strategic development
5.3.1.2 Technology
5.3.1.3 Patent
5.3.2 XXXX
5.3.3 XXXX
5.3.3.1 Pre-Clinical studies
5.3.3.2 Strategic development
5.3.3.3 Grant
5.4 Discovery
5.4.1 XXXX
5.5 Discontinued
5.5.1 XXXX
Chapter 6. Clinical Trials Review
6.1 Clinical Trials by Region
6.2 Clinical Trials by Trial Status
Chapter 7. Competitive Landscape
7.1 Key Players Benchmarking
7.2 Patents for Achondroplasia
7.3 SWOT Analysis
7.3.1 Strengths
7.3.2 Weaknesses
7.3.3 Opportunities
7.3.4 Threats
Chapter 8. Company Profiles
8.1 Ascendis Pharma A/S
8.1.1 Business Overview
8.1.2 Product and Service Offerings
8.2 RIBOMIC Inc.
8.2.1 Business Overview
8.2.2 Product and Service Offerings
8.3 XXXX
8.3.1 Business Overview
8.3.2 Product and Service Offerings
8.4 XXXX
8.4.1 Business Overview
8.4.2 Product and Service Offerings
8.5 XXXX
8.5.1 Business Overview
8.5.2 Product and Service Offerings
8.6 XXXX
8.6.1 Business Overview
8.6.2 Product and Service Offerings
8.7 BioMarin Pharmaceutical Inc.
8.7.1 Business Overview
8.7.2 Product and Service Offerings
8.8 XXXX
8.8.1 Business Overview
8.8.2 Product and Service Offerings
Chapter 9. Appendix
9.1 Abbreviations
9.2 Related Reports
LIST OF TABLES
TABLE 1 PIPELINE ANALYSIS OF ACHONDROPLASIA THERAPEUTICS, BY COMPANY (2018)
TABLE 2 DESCRIPTION OF VOSORITIDE
TABLE 3 CLINICAL TRIALS OF VOSORITIDE
TABLE 4 PHASE II TRIAL DISPOSITION AND DEMOGRAPHICS
TABLE 5 CLINICAL RESULTS OF VOSORITIDE
TABLE 6 DESCRIPTION OF TRANSCON CNP
TABLE 7 CLINICAL TRIALS OF TRANSCON CNP
TABLE 8 DESCRIPTION OF XXXX
TABLE 9 DESCRIPTION OF XXXX
TABLE 10 DESCRIPTION OF XXXX
TABLE 11 DESCRIPTION OF XXXX
TABLE 12 DESCRIPTION OF XXXX
TABLE 13 DESCRIPTION OF XXXX
TABLE 14 DESCRIPTION OF XXXX
TABLE 15 ASCENDIS PHARMA A/S – AT A GLANCE
TABLE 16 RIBOMIC INC. – AT A GLANCE
TABLE 17 XXXX – AT A GLANCE
TABLE 18 XXXX – AT A GLANCE
TABLE 19 XXXX – AT A GLANCE
TABLE 20 XXXX – AT A GLANCE
TABLE 21 BIOMARIN PHARMACEUTICAL INC. – AT A GLANCE
TABLE 22 XXXX – AT A GLANCE
LIST OF FIGURES
FIG 1 RESEARCH METHODOLOGY
FIG 2 BREAKDOWN OF PRIMARY RESEARCH BY PRIMARY RESPONDANTS
FIG 3 BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE
FIG 4 ACHONDROPLASIA THERAPEUTICS UNDER DEVELOPMENT (2018)
FIG 5 ACHONDROPLASIA THERAPEUTICS PIPELINE SPLIT, BY MOLECULE TYPE (2018)
FIG 6 ACHONDROPLASIA THERAPEUTICS PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2018)
FIG 7 TRANSCON TECHNOLOGY
FIG 8 RIBOART SYSTEM
FIG 9 BREAKDOWN OF CLINICAL TRIALS, BY REGION
FIG 10 BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS
FIG 11 KEY PLAYERS BENCHMARKING
FIG 12 SWOT ANALYSIS